Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy
Pacira BioSciences issued a detailed statement addressing inaccurate claims made by activist investor DOMA Perpetual regarding the company's intellectual property strategy protecting its flagship non-opioid pain therapy, EXPAREL. The company highlighted the strength and recent reinforcements of its patent estate, ongoing litigation efforts against …